Chimerigen

CD279 [PD-1] (human) (rec.) (His)

CHF 430.00
In stock
CHI-HF-201PD1-C100100 µgCHF 430.00
More Information
Product Details
Synonyms PD-1; Programmed Cell Death Protein 1
Product Type Protein
Properties
Source/Host HEK 293 cells
Sequence

The extracellular domain of human CD279 [PD-1] (aa 25-167) is fused at the C-terminus to a His-tag.

Crossreactivity Human
Biological Activity

Measured by its binding ability in a functional ELISA.

MW ~30kDa (SDS-PAGE)
Purity ≥95% (SDS-PAGE)
Endotoxin Content <1EU/mg protein (LAL test; Lonza).
Reconstitution Reconstitute with sterile water to a concentration of 0.5mg/ml.
Add 1X PBS to the desired protein concentration.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Other Product Data

NCBI reference NP_005009.2: CD279 (human)

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

CD279 (Programmed Cell Death Protein 1; PD-1) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immunoreceptors that mediate signals for regulating immune responses. Members of the CD28/CTLA-4 family have been shown to either promote T cell activation (CD28 and ICOS) or downregulate T cell activation (CTLA-4 and PD-1). CD279 is expressed on activated T cells, B cells, myeloid cells and on a subset of thymocytes. In vitro, ligation of CD279 inhibits TCR-mediated T cell proliferation and production of IL-1, IL-4, IL-10 and IFN-γ. In addition, CD279 ligation also inhibits BCR mediated signaling. CD279 deficient mice have a defect in peripheral tolerance and spontaneously develop autoimmune diseases.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.